Related Experiment Video
Updated: Aug 19, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Melatonin modulates aromatase activity in MCF-7 human breast cancer cells
Samuel Cos1, Carlos Martínez-Campa, Maria D Mediavilla
1Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Spain.
Abstract:
Most of the current knowledge about the mechanisms by which melatonin inhibits the growth of breast cancer cells point to an interaction of melatonin with estrogen-responsive pathways, thus behaving as an antiestrogenic hormone. However, a possible effect of melatonin on the local synthesis of estrogens had not been examined. The objective of this work was to study whether melatonin may modify the aromatase activity in MCF-7 breast cancer cells thus modulating the local estrogen biosynthesis. In MCF-7 cells cultured with testosterone in estradiol-free media, melatonin (1 nM) counteracts the testosterone-induced cell proliferation dependent on the local biosynthesis of estrogens from testosterone by the aromatase activity of the cells. We found that melatonin reduces the aromatase activity (measured by the tritiated water release assay) of MCF-7 cells both at basal conditions and when aromatase activity was stimulated by cAMP or cortisol. The greatest inhibition of the aromatase activity was obtained with 1 nm melatonin, the same concentration that gives the highest antiproliferative and anti-invasive effects of MCF-7 cells. Finally, by RT-PCR, we found that melatonin downregulates aromatase expression at the transcriptional level in the MCF-7 cells. We conclude that melatonin, at physiological concentrations, decreases aromatase activity and expression in MCF-7 cells. This aromatase inhibitory effect of melatonin, together with its already known antiestrogenic properties interacting with the estrogen-receptor, makes this indoleamine an interesting tool to be considered in the prevention and treatment of hormone-dependent mammary neoplasias.
Insights
Melatonin, a hormone, inhibits breast cancer cell growth by reducing aromatase activity and expression. This indoleamine offers potential for preventing and treating hormone-dependent mammary cancers.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Melatonin is known to inhibit breast cancer cell growth, primarily through antiestrogenic mechanisms.
- The effect of melatonin on local estrogen synthesis, specifically aromatase activity, in breast cancer cells remains largely unexamined.
Purpose of the Study:
- To investigate whether melatonin modulates aromatase activity and estrogen biosynthesis in MCF-7 breast cancer cells.
- To determine the impact of melatonin on testosterone-induced proliferation in MCF-7 cells, which relies on local estrogen production.
Main Methods:
- MCF-7 cells were cultured with testosterone in estradiol-free media.
- Aromatase activity was measured using the tritiated water release assay.
- Gene expression of aromatase was analyzed using RT-PCR.
Main Results:
- Melatonin (1 nM) counteracted testosterone-induced proliferation in MCF-7 cells.
- Melatonin significantly reduced basal and stimulated aromatase activity in MCF-7 cells.
- Melatonin downregulated aromatase expression at the transcriptional level in MCF-7 cells.
Conclusions:
- Melatonin, at physiological concentrations, inhibits both the activity and expression of aromatase in MCF-7 breast cancer cells.
- This inhibition of local estrogen biosynthesis, combined with known antiestrogenic effects, positions melatonin as a potential therapeutic agent for hormone-dependent breast cancer.

